Genentech's Lucentis approved for diabetic eye disease

Genentech Inc.'s eye drug Lucentis won FDA approval Friday to treat diabetic patients for a blinding disease. South San Francisco-based Genentech, part of Swiss drug maker Roche, was recommended last month by a Food and Drug Administration advisory panel as a treatment for diabetic macular edema.